恶性淋巴增生包括淋巴瘤、急性淋巴细胞白血病和慢性淋巴细胞白血病。
Lymphoproliferative malignancies include lymphomas and acute lymphoblastic and chronic lymphocytic leukemias.
相对于急性白血病，慢性淋巴细胞白血病和慢性粒细胞性白血病通常进展缓慢。
Chronic lymphocytic leukemia and chronic myelogenous leukemia usually progress slowly compared to acute leukemias.
与其他三种类型的白血病不同，慢性淋巴细胞白血病患者可能会有一些持续时间不长的病症。
Unlike the other three types of leukemia, some patients with CLL may have disease that does not progress for a long time.
慢性中性粒细胞白血病和慢性淋巴细胞白血病均未发现CD 133的阳性表达。
There were no expression of CD133 in chronic neutrophilic leukemia (CNL) and chronic lymphocytic leukemia (CLL) patients.
有些病人在常规体检的血液检查后才知道他们患有慢性淋巴细胞白血病或慢性粒细胞性白血病。
Some patients learn they have CLL or CML after a blood test as part of a regular checkup.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
目的探讨嘌呤能P2 Z受体介导慢性淋巴细胞白血病（CL L ）细胞凋亡的影响因素及其机理。
Objective To explore the effects of various factors affecting apoptosis of chronic lymphocytic leukemia (CLL) cells mediated by P2Z purinoceptor.
目的探讨多重荧光原位杂交(M -FISH)技术检测慢性淋巴细胞白血病(CLL)复杂核型异常(CCA)的价值。
Objective To investigate the value of multiplex fluorescence in situ hybridization (M-FISH) in the detection of complex chromosomal abnormalities (CCAs) of chronic lymphocytic leukemia (CLL).
美国每年约有10,000人被诊断为慢性淋巴细胞性白血病，慢淋目前是不可治愈的。
Each year, about 10,000 people in the United States are diagnosed with CLL, which is currently incurable.
一些慢性淋巴细胞性白血病CLL患者在确诊后较长时间内并不急需移植疗法。
Some CLL patients do not need treatment for long periods of time after diagnosis.
慢性淋巴细胞性白血病，出现淋巴结肿大较早。
Lymph node enlargement occurs early in chronic lymphocytic leukemia.
结论免疫表型分析是诊断慢性淋巴细胞系统白血病非常有用的依据。
Conclusion immunophenotypic analysis is an extremely useful adjunct in the diagnosis of chronic lymphoid leukemia.
近来，研究发现急性淋巴细胞白血病(all)和慢性粒细胞白血病(CML)患者血清中il - 18水平高于正常人。
Recently, elevated IL-18 levels were found in serum from some leukemia patients, especially those with acute lymphocytic leukemia (all) and chronic myeloid leukemia (CML).
他们发现通过这种试验，试验*物ABT-737易于标记慢性淋巴细胞性白血病。
Using the test, they found that chronic lymphocytic leukemia (CLL) is an "easy mark" for the experimental drug ABT-737.
“慢性”白血病少有或几乎没有母细胞。与急性白血病相比，“慢性淋巴细胞性白血病”和“慢性髓细胞性白血病”通常进程相对缓慢。
"Chronic" leukemias have few or no blast cells. "chronic lymphocytic leukemia" and "chronic myelogenous leukemia" usually progress slowly compared to acute leukemias.
慢性淋巴细胞性白血病的细胞依赖生存分子Bcl - 2，该分子可以关闭了癌症细胞的凋亡信号。
CLL cells are strongly dependent on a survival molecule called Bcl-2, which switches off self-destruct signals in the cancer cells.
慢性淋巴细胞性白血病的细胞依赖生存分子Bcl - 2，该分子可以关闭了癌症细胞的凋亡信号。
CLL cells are strongly dependent on a survival molecule called Bcl-2, which switches off self-destruct signals in the cancer cells.
应用推荐